PT Darya-Varia Laboratoria Tbk

IDX:DVLA Stock Report

Market Cap: Rp1.8t

Darya-Varia Laboratoria Past Earnings Performance

Past criteria checks 4/6

Darya-Varia Laboratoria's earnings have been declining at an average annual rate of -11.6%, while the Pharmaceuticals industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 1.4% per year. Darya-Varia Laboratoria's return on equity is 13.1%, and it has net margins of 9.1%.

Key information

-11.6%

Earnings growth rate

-11.7%

EPS growth rate

Pharmaceuticals Industry Growth20.4%
Revenue growth rate1.4%
Return on equity13.1%
Net Margin9.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Darya-Varia Laboratoria makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

IDX:DVLA Revenue, expenses and earnings (IDR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,134,031193,905861,6830
30 Jun 241,995,668169,381820,8500
31 Mar 241,910,016152,911804,3510
31 Dec 231,890,888146,336797,5160
30 Sep 231,739,18983,901800,9340
30 Jun 231,815,69376,354848,5850
31 Mar 231,783,94873,275838,0270
31 Dec 221,917,041149,375830,4270
30 Sep 221,856,94543,735902,0830
30 Jun 222,009,621182,520836,6090
31 Mar 222,058,892202,596822,5500
31 Dec 211,900,894146,505806,0710
30 Sep 212,120,581282,843760,2330
30 Jun 211,876,676156,427749,7780
31 Mar 211,834,423186,516703,3530
31 Dec 201,829,700162,073726,5480
30 Sep 201,680,412191,500640,3920
30 Jun 201,827,255246,976656,6090
31 Mar 201,814,913195,056704,9920
31 Dec 191,813,020221,783678,0040
30 Sep 191,875,188214,986725,2810
30 Jun 191,799,139206,116699,0690
31 Mar 191,750,915221,007659,4710
31 Dec 181,699,657200,652675,3360
30 Sep 181,598,083153,113686,4450
30 Jun 181,597,357149,482693,7980
31 Mar 181,607,717141,526717,5290
31 Dec 171,575,647162,249681,3390
30 Sep 171,515,073187,072636,3470
30 Jun 171,479,646189,754614,1370
31 Mar 171,470,354179,081603,7250
31 Dec 161,451,357152,083596,5070
30 Sep 161,472,526147,533595,3550
30 Jun 161,399,810113,992599,2840
31 Mar 161,343,054104,633580,1920
31 Dec 151,306,098107,894558,1350
30 Sep 151,269,185101,501534,5690
30 Jun 151,290,566108,668526,5460
31 Mar 151,228,853158,858465,1390
31 Dec 141,103,82281,598486,3450
30 Sep 141,073,326108,552451,6400
30 Jun 14985,45397,391449,8950
31 Mar 141,032,13764,584523,4050
31 Dec 131,101,684125,796511,7480

Quality Earnings: DVLA has high quality earnings.

Growing Profit Margin: DVLA's current net profit margins (9.1%) are higher than last year (4.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DVLA's earnings have declined by 11.6% per year over the past 5 years.

Accelerating Growth: DVLA's earnings growth over the past year (131.1%) exceeds its 5-year average (-11.6% per year).

Earnings vs Industry: DVLA earnings growth over the past year (131.1%) exceeded the Pharmaceuticals industry 4%.

Return on Equity

High ROE: DVLA's Return on Equity (13.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 05:09
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PT Darya-Varia Laboratoria Tbk is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution